Home   »  TRADE TOPICS  »  Prescription Drugs  »  Public Leadership

Public Leadership

General Content
Letter from Five State Legislators to U.S. Trade Representative Ron Kirk
September 16th, 2010
ME Sen. Peggy Rotundo, ME Rep. Sharon Anglin Treat, VT Rep. Ginny Lyons, VT Rep. Kathleen Keenan, and NH Rep. Charles Reed have asked Ambassador Kirk to ensure that the TPP will not include provisions that limit the negotiation of drug prices.
Vermont Commission on International Trade and State Sovereignty Letter to President Obama
August 27th, 2010
Sen. Ginny Lyons and Rep. Kathleen Keenan write President Obama, warning that the investment and pharmaceutical chapters of the US-Korea FTA will harm state interests.
Letter from VT Governor Douglas to DHHS Secretary Sebelius
May 3rd, 2010
Gov. Douglas calls attention to previous messages from states asking that matters relating to pharmaceutical pricing be taken out of the Special 301 Report.
Letter from ME Governor Baldacci to DHHS Secretary Kathleen Sebelius
Governor Baldacci argues that pharmaceutical pricing policy does not belong in USTR's Annual Special 301 Report, and should be omitted from the report in 2010.
NLARx Comments to U.S. Trade Representative on the Korea-U.S. Free Trade Agreement
September 15th, 2009
Comments from ME Representative Sharon Treat on the pending free trade agreement with Korea, focusing on provisions on pharmaceuticals and medical devices.
Letter from VT Commission on International Trade and State Sovereignty to Federal Congressional Delegation
April 18th, 2007
VT State Sen. Ginny Lyons and State Representative Kathleen Keenan write US Sen. Leahy, Sen. Sanders, and Rep. Welch about the Korea-US Free Trade Agreement.
NLARx Testimony before the U.S. House Committee on Ways and Means Subcommittee on Trade
March 20th, 2007
Testimony by Counsel Sean Flynn on the intellectual property and pharmaceuticals chapters of the Korea-US Free Trade Agreement.
NLARx Letter to the U.S. Senate Finance Committee on the Negotiation of Drug Prices
January 11th, 2007
Maine State Representative Sharon Treat describes the savings and mechanics of Medicaid Preferred Drug Lists.
Gov. Gregoire Letter to USTR on Pharmaceuticals
March 13th, 2006
Letter from the governor of Washington state warning the US Trade Representative about the conflict between FTAs and state programs to control drug costs.
Washington Legislators on the US-Australia FTA
March 2nd, 2006
Four legislators write the US Congressional delegation about the potential conflict between the trade agreement and state Medicaid programs.
Vermont Joint Resolution Relating to International Trade Agreements and Pharmaceutical Drug Programs. (J.R.S.50)
November 30th, 2005
Resolution on Annex 2(c) of the Australia-US FTA sponsored by Senators Lyons, Ayer, Bartlett, Campbell, Collins, Condos, Cummings, Dunne, Gander, Giard, Illuzzi, Kitchel, Kittell, Leddy, MacDonald, Miller, Mullin, Scott, Sears, Welch and White.
Letter from Nine State Senators and Representatives to U.S. Trade Representative Robert Zoellick
October 20th, 2005
Letter from NLARx Legislative Working Group on Trade and Prescription Drugs signed by State Representatives Kevin Ryan (CT), Meg Burton-Cahill (AZ), Roy Takumi (HI), Maralyn Chase (WA), David Guttenberg (AK), and John Patrick (ME), and State Senators Mark Montigny (MA), Liz Figueroa (CA), and Dan Foster (WV).
Legislative Working Group on Prescription Drugs' Letter to USTR
August 20th, 2005
The Working Group asks USTR for further information about the possible effect of free trade agreements on state Medicaid drug price negotiations, pharmaceutical reimportation, and GATS.
California State Senators Figueroa and Kuhl Letter to USTR
February 16th, 2005
California Senate Select Committee on International Trade Policy leadership asks about provisions on prescription drugs in the US-Australia FTA.

Unless otherwise expressly stated, all original material of whatever nature created by the Forum on Democracy & Trade website is licensed under a Creative Commons License. Privacy Statement | Sitemap